TNFRSF18 and neoplasm: However, clinical trials of GITR agonists, TRX518, AMG228, MK-1248, MK-4166, BMS986156, MEDI18730, and GWN323 showed limited antitumor activities in monotherapy, although with tolerable safety profiles.675–681 These studies have implicated that GITR agonists alone could not reactivate the cytolytic function of T cells in tumor environment, and combinatorial approaches of GITR agonism and other immunomodulatory therapies are of great interest.